There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual antiplatelet therapy (DAPT) for 12 months would not be advisable. Even though the European and American guidelines recommend 1 to 6 months for chronic and acute syndromes in this group, these are often complex PCI cases, which makes<a href="https://solaci.org/en/2022/07/04/two-safe-stents-at-two-years-in-high-bleeding-risk/" title="Read more" >...</a>
Stroke is one of the leading causes of death and disability. It produces great morbidity by causing marked post-event cognitive impairment. Recurrence of an ischemic event may vary according to the cause of the stroke. Complicated non-stenotic carotid plaque (CCP) type VI (according to the American Heart Association [AHA] classification) has been described as an<a href="https://solaci.org/en/2022/06/27/complicated-non-stenotic-carotid-plaques-a-light-in-the-diagnosis-of-cryptogenic-stroke/" title="Read more" >...</a>
Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized studies have shown their effectiveness and benefit in femoropopliteal territory, and even though the use of paclitaxel coated balloons has been called into question, a retrospective study including 168,553 patients was able to show paclitaxel coated balloons were<a href="https://solaci.org/en/2022/06/27/in-pact-global-follow-up-of-real-life-patient-in-femoropopliteal-territory/" title="Read more" >...</a>
The proportion of patients treated with coronary angioplasty who are at a high risk for bleeding is increasing. In this population, extended dual antithrombotic therapy increases the risk of bleeding. The 1-year randomized Onyx one study has demonstrated the non-inferiority of zotarolimus-eluting stents (ZES) vs. biolimus-coated polymer-free stent BioFreedom (DCS). Patients received dual-antiplatelet therapy (DAPT)<a href="https://solaci.org/en/2022/06/22/results-of-zotarolimus-eluting-stents-vs-biolimus-eluting-polymer-free-stents-after-2-years-are-they-safe-in-patients-at-high-risk-for-bleeding/" title="Read more" >...</a>
New revascularization after coronary artery bypass graft (CABG) is often needed, be it because of severe bridge lesion, intimal hyperplasia, thrombosis, atherosclerosis, or native vessel lesion progression. We therefore need to determine the best revascularization strategy, namely native or graft percutaneous intervention, venous or arterial, or repeat surgery, with the risk it entails. There is<a href="https://solaci.org/en/2022/06/21/pci-on-native-arteries-or-saphenous-vein-grafts-which-has-better-prognosis/" title="Read more" >...</a>
In general, thrombus aspiration in acute myocardial infarction (AMI) has not been shown beneficial by large studies. It could even be prejudicial, since it has been associated with stroke. However, there are certain scenarios where the presence of a significant number of these prevents us from reaching adequate TIMI flow 3, or is associated with<a href="https://solaci.org/en/2022/06/15/the-current-role-of-thrombus-aspiration-in-primary-pci/" title="Read more" >...</a>
Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic stents are permanent foreign bodies that activate the entire inflammatory system. Using bioresorbable stents (BRS) emerged as an alternative to this challenge. Although the initial results of the ABSORB study were not as expected (probably due to a<a href="https://solaci.org/en/2022/06/09/should-we-start-thinking-again-about-bioresorbable-stents/" title="Read more" >...</a>
Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular. Therefore, they are associated with thromboembolic and bleeding risk. This study looked mortality predictors after successful TAVR in the Galileo trial. Mortality at 248 days was 9.2%, 5.5% being of cardiovascular cause and 3.9% non-cardiovascular. Mortality predictors were age >85,<a href="https://solaci.org/en/2022/05/23/europcr-2022-galileo-trial-mortality-predictors-after-successful-tavr/" title="Read more" >...</a>
It has been long since the SYNTAX (NEJM 2009) came out comparing percutaneous coronary intervention (PCI) against coronary artery bypass grafting (CABG). That emblematic study associated PCI with first generation drug eluting stents (Taxus) with increased major cardiac and cerebrovascular events (all-cause mortality, AMI, stroke, or any revascularization – MACCE) vs. CABG, at 5 years,<a href="https://solaci.org/en/2022/05/05/coronary-angioplasty-evolution-according-to-syntax-ii-5-year-followup/" title="Read more" >...</a>
The incidence of left ventricular thrombosis (LVT) after anterior ST-segment elevation myocardial infarction (STEMI) ranges from 4% to 26%. This is associated with bad long-term evolution. In the past, triple-scheme therapy (vitamin K antagonist plus dual antiplatelet therapy) was recommended to prevent LVT, despite the lack of high-quality scientific evidence and an increase in the<a href="https://solaci.org/en/2022/05/05/prophylactic-rivaroxaban-therapy-for-left-ventricular-thrombus-after-st-segment-elevation-acute-coronary-syndrome/" title="Read more" >...</a>